Danske Bank A S Takes $14.21 Million Position in IQVIA Holdings Inc. $IQV

Danske Bank A S purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 73,566 shares of the medical research company’s stock, valued at approximately $14,214,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Apella Capital LLC boosted its holdings in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after buying an additional 58 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of IQVIA by 1.3% during the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after acquiring an additional 60 shares during the period. Private Advisor Group LLC lifted its position in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. Breakwater Capital Group boosted its stake in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after purchasing an additional 64 shares during the period. Finally, Keybank National Association OH grew its position in IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 67 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is owned by corporate insiders.

IQVIA Trading Up 3.0%

Shares of IQVIA stock opened at $256.66 on Friday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $260.30. The company has a market cap of $42.25 billion, a price-to-earnings ratio of 31.84, a PEG ratio of 2.12 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company’s fifty day simple moving average is $211.74 and its 200-day simple moving average is $187.01.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of analysts have recently issued reports on IQV shares. Robert W. Baird increased their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. BMO Capital Markets increased their price objective on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.